Protara Therapeutics Inc TARA
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2014-10-22 |
| Shares Out. | 56,200,000 |
| Website | protaratx.com/ ↗ |
| Phone | 13026587581 |
| Employees | 51 |
| Revenue | $0 |
| Gross Profit | $0 |
| Net Income | -$21.7M |
| Free Cash Flow | -$66.5M |
| Total Assets | $176.1M |
| Total Liabilities | $14.8M |
| Equity | $161.3M |
About Protara Therapeutics Inc
Protara Therapeutics Inc is a clinical-stage biopharmaceutical company focused on advancing its therapies for the treatment of cancer and rare diseases. Its drug development pipeline includes: TARA-002, an investigational cell therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs); and IV Choline Chloride, an investigational phospholipid substrate replacement therapy, for patients receiving parenteral support, or PS, which includes both nutrition and fluids.
Protara Therapeutics Inc is a publicly traded company under the ticker symbol TARA on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
14 analysts (2026-09-01)